SCHEMBL5328162

SCHEMBL5328162

Nc1nc(-c2cc3ccccc3o2)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 1.00
RAB9A P51151 9/20 1.00
MAPT P10636 7/20 1.00
CYP19A1 P11511 1/20 0.61
SMN1; SMN2 Q16637 8/20 0.58
STAT1 P42224 1/20 0.58
GRM4 Q14833 1/20 0.58
ALDH1A1 P00352 6/20 0.56
KDM4E B2RXH2 4/20 0.56
NFKB1 P19838 4/20 0.56
NFKB2 Q00653 4/20 0.56
RELA Q04206 4/20 0.56
LMNA P02545 2/20 0.55
TP53 P04637 1/20 0.55
HPGD P15428 1/20 0.55
AR P10275 1/20 0.51
GFER P55789 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
METAP2 P50579 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12647915 0.81 NPC1 (0.69) NPC1RAB9AMAPTCYP19A1SMN1; SMN2
SCHEMBL3139823 0.80 MAPT (0.66) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL30315706 0.80 MAPT (0.66) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL21823774 0.79 CYP19A1 (0.69) NPC1RAB9AMAPTCYP19A1SMN1; SMN2
SCHEMBL30723290 0.78 NPC1 (0.72) NPC1RAB9AMAPTCYP19A1SMN1; SMN2
SCHEMBL12591868 0.78 NPC1 (0.63) NPC1RAB9AMAPTCYP19A1SMN1; SMN2
SCHEMBL29152947 0.78 NPC1 (0.72) NPC1RAB9AMAPTCYP19A1SMN1; SMN2
SCHEMBL14936927 0.77 MAPT (0.62) NPC1RAB9AMAPTCYP19A1SMN1; SMN2
SCHEMBL8863943 0.76 RAB9A (0.61) NPC1RAB9AMAPTCYP19A1SMN1; SMN2
SCHEMBL8863964 0.76 GRM4 (0.62) NPC1RAB9AMAPTCYP19A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2597093-B1 BENZOFURANONE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FUSO PHARMACEUTICAL IND (JP) 2014-11-05 EP claimed
US-8563743-B2 Benzofuranone compound and pharmaceutical composition containing same FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2013-10-22 US claimed
EP-2597093-A1 BENZOFURANONE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Fuso Pharmaceutical Industries, Ltd. (JP) 2013-05-29 EP claimed
US-20130123313-A1 BENZOFURANONE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2013-05-16 US claimed
CN-117486872-A Mechanical ball milling synthesis method of aminothiazole compound 浙江工业大学 2024-02-02 CN disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
US-7968577-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2011-06-28 US disclosed
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed
WO-2008057862-A2 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-15 WO disclosed
US-20070299113-A1 Metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO. KGAA (DE) 2007-12-27 US disclosed
WO-2007148113-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2007-12-27 WO disclosed
US-5679678-A ANALGESIC AND ANTIINFLAMMATORY AGENTS CHEMISCH PHARMAZEUTISCHE FORSCHUNGSGESELLSCHAFT M.B.H. (AT) 1997-10-21 US disclosed
EP-0658559-A1 Thienothiazin derivatives, process for their preparation and their use as 5-dipoxygenase and cyclooxygenase inhibitors Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. (AT) 1995-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 NPC1 3091/4885RAB9A 2879/4885MAPT 706/4885
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NFKB2, NFKBIA NPC1 1595/4885RAB9A 2635/4885MAPT 1222/4885
US-20130123313-A1 BENZOFURANONE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC10, RB1 NPC1 215/4885RAB9A 1628/4885MAPT 3760/4885
US-20070299113-A1 Metabotropic glutamate receptor modulators GRM1, GRM2, GRM3 NPC1 1076/4885RAB9A 1693/4885MAPT 794/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 NPC1 3091/4885RAB9A 2879/4885MAPT 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.